---
title: "Crystalys Therapeutics appoints Justin Thacker as CFO to aid Phase 3 trials of Dotinurad in gout treatment."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273237282.md"
description: "On January 21, 2026, in San Diego, Crystalys Therapeutics, Inc. disclosed the appointment of Justin Thacker as part of their initiative to cater to the medical requirements of individuals affected by gout. Crystalys, a company in the clinical-stage biopharmaceutical sector, aims to address the pressing needs of those living with gout. This move signifies a step towards fulfilling their objectives in this field."
datetime: "2026-01-21T13:11:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273237282.md)
  - [en](https://longbridge.com/en/news/273237282.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273237282.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273237282.md) | [繁體中文](https://longbridge.com/zh-HK/news/273237282.md)


# Crystalys Therapeutics appoints Justin Thacker as CFO to aid Phase 3 trials of Dotinurad in gout treatment.

On January 21, 2026, in San Diego, Crystalys Therapeutics, Inc. disclosed the appointment of Justin Thacker as part of their initiative to cater to the medical requirements of individuals affected by gout. Crystalys, a company in the clinical-stage biopharmaceutical sector, aims to address the pressing needs of those living with gout. This move signifies a step towards fulfilling their objectives in this field.

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Cyclerion Therapeutics, Inc. (CYCN.US)](https://longbridge.com/en/quote/CYCN.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Fulcrum Therapeutics, Inc. (FULC.US)](https://longbridge.com/en/quote/FULC.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md)
- [Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference](https://longbridge.com/en/news/277932414.md)
- [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)
- [Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen](https://longbridge.com/en/news/277784572.md)
- [BUZZ-MAIA Biotechnology plunges after $30 million share sale](https://longbridge.com/en/news/277605454.md)